Publications by authors named "Y Itano"
Aim: Recently, we demonstrated the efficacy of etelcalcetide in the control of secondary hyperparathyroidism (SHPT). This post hoc analysis aimed to evaluate changes in fibroblast growth factor-23 (FGF23) and calciprotein particles (CPPs) after treatment with calcimimetics.
Methods: The DUET trial was a 12-week multicenter, open-label, parallel-group, randomized (1:1:1) study with patients treated with etelcalcetide plus active vitamin D (E + D group; n = 41), etelcalcetide plus oral calcium (E + Ca group; n = 41), or control (C group; n = 42) under maintenance haemodialysis.
Time Series Analysis of Climate and Air Pollution Factors Associated with Atmospheric Nitrogen Dioxide Concentration in Japan.
Int J Environ Res Public Health
December 2020
Article Synopsis
- Nitrogen dioxide (NO), a pollutant from human activities, is analyzed alongside nitrous acid (HONO), which may have a greater impact on respiratory health, as they exist in an equilibrium affected by climate conditions.
- The study compares HONO levels in NO across urban areas (Tokyo, Osaka, Aichi) and rural areas (Yamanashi) in Japan, using data from 2009-2017.
- Findings suggest air temperature negatively influences NO levels, indicating HONO decomposition, while humidity's role varies, particularly showing a positive link only in Yamanashi, hinting at different HONO proportions in urban versus rural settings.
Introduction: The clinical trial on the Development of a treatment strategy for chronic kidney disease‒mineral and bone disorder by a mUltilateral mechanism of ETelcalcetide hydrochloride, or the DUET trial, was designed to determine the efficacy of etelcalcetide, an intravenous calcimimetic, for control of secondary hyperparathyroidism (SHPT).
Methods: Eligible SHPT maintenance hemodialysis patients (n = 124) were randomized (1:1:1) for inclusion in the DUET trial, a 12-week, multicenter, open-label, parallel-group study (jRCTs041180108), and assigned to either an etelcalcetide + active vitamin D group (group E+D), an etelcalcetide + oral calcium preparation group (group E+Ca), or a control group (group C). The primary endpoint was number of patients with a 50% reduction from baseline of intact parathyroid hormone (iPTH) levels, and iPTH levels ≤ 240 pg/mL at 12 weeks after start of the trial.
Article Synopsis
- The study investigates how urinary glucose excretion relates to kidney function in diabetes patients who aren't using sodium-glucose cotransporter 2 inhibitors.
- It included 1,172 diabetes patients and found that those with high urinary glucose (≥5 g/day) had better kidney function prognosis, showing a reduced risk of significant kidney decline.
- The results also indicated that this positive association was stronger in men and in patients who had diabetes for 10 or more years, suggesting urinary glucose can help predict kidney health in these individuals.